Fatty Liver Treatment Market 2025-2029: Unveiling Growth Developments with the Latest Updates

 Tailored for companies operating in or entering the fatty liver treatment sector, this analysis highlights core growth drivers, risks, and innovation trends.

 

 Fatty Liver Treatment Market Valuation Forecast: What Will The Market Be Worth By 2025?
 The fatty liver treatment market size has grown strongly in recent years. It will grow from $23.73 billion in 2024 to $25.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to obesity epidemic, sedentary lifestyles, unhealthy diets, limited treatment options, awareness campaigns.
 
 The fatty liver treatment market size is expected to see strong growth in the next few years. It will grow to $32.98 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increased disease prevalence, rising healthcare expenditure, growing diabetes and metabolic syndrome, innovation in therapeutics. Major trends in the forecast period include precision medicine approaches, lifestyle modification programs, targeted therapies for Nash, non-invasive monitoring tools, technological advancements.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=12581&type=smp
 
 What Are The Key Factors Driving Growth In The Fatty Liver Treatment Market?
 The increase in alcohol consumption is expected to propel the growth of the fatty liver treatment market going forward. Alcohol consumption refers to consuming beverages containing alcohol, a psychoactive substance with depressant effects on the central nervous system. Alcohol consumption can worsen fatty liver disease and lead to more severe liver conditions, including alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For instance, in March 2023, according to the HRB National Drugs Library, an Ireland-based government-funded organization, in 2022, alcohol consumption in Scotland increased to 10.2 liters of pure alcohol per capita for individuals over the age of 15, reflecting a 7.6% rise compared to 2021, highlighting a concerning upward trend in alcohol intake amidst ongoing public health efforts to reduce consumption. Therefore, the increase in alcohol consumption is driving the growth of the fatty liver treatment market. 
 
 Emerging And High-Growth Segments In The Global Fatty Liver Treatment Market
 The fatty liver treatmentmarket covered in this report is segmented — 
 
 1) By Treatment Type: Anti-Rejection Drugs Or Immunosuppressants; Chemotherapy Drugs; Targeted Therapy; Vaccines; Anti-Viral Drugs
 2) By Disease Type: Hepatitis; Liver Cancer; Non-Alcoholic Fatty Liver Disease; Other Diseases
 3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
 
 Subsegments:
 1) By Anti-Rejection Drugs Or Immunosuppressants: Corticosteroids; Calcineurin Inhibitors; mTOR Inhibitors 
 2) By Chemotherapy Drugs: Conventional Chemotherapy Agents; Novel Chemotherapeutics Under Investigation 
 3) By Targeted Therapy: Small Molecule Inhibitors; Monoclonal Antibodies 
 4) By Vaccines: Therapeutic Vaccines; Preventive Vaccines 
 5) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs); Nucleos(t)ide Analogs 
 
 Fatty Liver Treatment Market Future Trends
 Product innovation is a key trend gaining popularity in the fatty liver treatment market. Major companies operating in fatty liver treatment are developing innovative products to strengthen their position in the market. For instance, in March 2023, Akero Therapeutics, a US-based biotechnology company, reported positive Phase II reports of efruxifermin, indicated for the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It is a differentiated Fc-FGF21 fusion protein that mimics the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes.
 
 Key Fatty Liver Treatment Company Insights:
 Major companies operating in the fatty liver treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, GlaxoSmithkline plc, Mitsubishi Chemical Holdings, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Eisai Co. Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, GW Pharmaceuticals Limited, Retrophin Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., AbbKine Scientific Co. Ltd., Daewoong Co. Ltd., Madrigal Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Limited, Genfit, NGM Biopharmaceuticals Inc., Cardax Inc., Conatus Pharmaceuticals Inc., Limerick Biopharma Inc. 
 
 View the full fatty liver treatment market report here:
 https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
 
 How Does Fatty Liver Treatment Market Growth Vary Across Major Regions?
 North America was the largest region in the fatty liver treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company